公开(公告)号：US20200140435A1

公开(公告)日：2020-05-07

申请号：US16720486

申请日：2019-12-19

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Motoyuki TANAKA ,  Takashi KONDO ,  Yasuo HIROOKA ,  Taihei NISHIYAMA ,  Atsushi HIRAMATSU ,  Tomoyuki KODA ,  Sho KOUYAMA

IPC: C07D471/04 ,  A61K31/444 ,  A61K9/20 ,  A61K31/519 ,  C07D487/04 ,  A61P43/00 ,  C07D401/14

Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.

公开(公告)号：US20190352304A1

公开(公告)日：2019-11-21

申请号：US16527489

申请日：2019-07-31

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Motoyuki TANAKA ,  Takashi KONDO ,  Yasuo HIROOKA ,  Taihei NISHIYAMA ,  Atsushi HIRAMATSU ,  Tomoyuki KODA ,  Sho KOUYAMA

IPC: C07D471/04 ,  A61P43/00 ,  C07D487/04 ,  A61K31/444 ,  A61K9/20 ,  A61K31/519

Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.

公开(公告)号：US20180334458A1

公开(公告)日：2018-11-22

申请号：US16050266

申请日：2018-07-31

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Motoyuki TANAKA ,  Takashi KONDO ,  Yasuo HIROOKA ,  Taihei NISHIYAMA ,  Atsushi HIRAMATSU ,  Tomoyuki KODA ,  Sho KOUYAMA

IPC: C07D471/04 ,  C07D487/04 ,  A61K31/519 ,  A61P43/00 ,  A61K9/20 ,  A61K31/444

CPC classification number: C07D471/04 ,  A61K9/20 ,  A61K31/444 ,  A61K31/519 ,  A61P43/00 ,  C07D487/04

Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.

公开(公告)号：US20220388955A1

公开(公告)日：2022-12-08

申请号：US17621137

申请日：2020-06-26

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Akio WATANABE ,  Atsushi YOSHIDA ,  Yasuo HIROOKA ,  Michael G. YANG ,  Ning LI

IPC: C07D207/34 ,  A61K31/40 ,  C07D401/12 ,  A61K31/4439 ,  C07C233/76 ,  A61K31/167 ,  C07D231/12 ,  A61K31/415 ,  C07D233/70 ,  A61K31/4174 ,  C07D213/75 ,  A61K31/44 ,  C07D241/18 ,  A61K31/4965 ,  C07D487/04 ,  A61K31/519 ,  C07D213/56 ,  C07C323/29 ,  A61K31/145 ,  A61P35/00

Abstract: A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, of formula (I-A): wherein all symbols have the same meanings as those described in the specification, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230138003A1

公开(公告)日：2023-05-04

申请号：US18088045

申请日：2022-12-23

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Motoyuki TANAKA ,  Takashi KONDO ,  Yasuo HIROOKA ,  Taihei NISHIYAMA ,  Atsushi HIRAMATSU ,  Tomoyuki KODA ,  Sho KOUYAMA

IPC: C07D471/04 ,  A61K31/444 ,  A61P43/00 ,  C07D401/14 ,  A61K9/20 ,  A61K31/519 ,  C07D487/04

Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.

公开(公告)号：US20210009586A1

公开(公告)日：2021-01-14

申请号：US17027922

申请日：2020-09-22

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Motoyuki TANAKA ,  Takashi KONDO ,  Yasuo HIROOKA ,  Taihei NISHIYAMA ,  Atsushi HIRAMATSU ,  Tomoyuki KODA ,  Sho KOUYAMA

IPC: C07D471/04 ,  A61K31/444 ,  A61P43/00 ,  C07D401/14 ,  A61K9/20 ,  A61K31/519 ,  C07D487/04

Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.

公开(公告)号：US20170349580A1

公开(公告)日：2017-12-07

申请号：US15534247

申请日：2015-12-09

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Motoyuki TANAKA ,  Takashi KONDO ,  Yasuo HIROOKA ,  Taihei NISHIYAMA ,  Atsushi HIRAMATSU ,  Tomoyuki KODA ,  Sho KOUYAMA

IPC: C07D471/04 ,  A61K31/519 ,  A61K31/444 ,  C07D487/04 ,  A61K9/20

CPC classification number: C07D471/04 ,  A61K9/20 ,  A61K31/444 ,  A61K31/519 ,  A61P43/00 ,  C07D487/04

Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.